Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left ventricular hypertrophy as a coronary risk factor.

F H Messerli1

  • 1Department of Internal Medicine, Ochsner Clinic, New Orleans, LA.

Blood Pressure. Supplement
|January 1, 1992
PubMed
Summary

Left ventricular hypertrophy (LVH) is a major risk factor for heart disease, leading to impaired heart function and myocardial ischemia. Understanding LVH is crucial for managing cardiovascular disease risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urocortin 2 - a protective effect in hypertension?

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2023
Same author

In vitro fertilization exacerbates stroke size and neurological disability in wildtype mice.

International journal of cardiology·2021
Same author

More SPRINT controversy.

Journal of internal medicine·2017
Same author

Optimal blood pressure targets in 2014 - Does the guideline recommendation match the evidence base?

Hipertension y riesgo vascular·2015
Same author

Cardioprotection with beta-blockers: myths, facts and Pascal's wager.

Journal of internal medicine·2009
Same author

Beta-blockers as fourth-line therapy for hypertension: stay the course.

International journal of clinical practice·2009

Area of Science:

  • Cardiology
  • Pathophysiology
  • Medical Science

Background:

  • Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular disease.
  • LVH is linked to impaired ventricular filling, arrhythmias, reduced contractility, and myocardial ischemia.
  • Myocardial ischemia in LVH results from increased oxygen demand and reduced supply due to vascular issues.

Purpose of the Study:

  • To elucidate the relationship between LVH and cardiovascular disease.
  • To detail the mechanisms linking LVH to impaired cardiac function and ischemia.

Main Methods:

  • Review of existing literature on LVH and cardiovascular disease.
  • Analysis of pathophysiological mechanisms.
  • Synthesis of clinical associations.

Main Results:

  • LVH is a primary driver of cardiovascular complications.
  • Impaired cardiac function and myocardial ischemia are direct consequences of LVH.
  • Multifactorial pathogenesis of ischemia involves hemodynamic burden, muscle mass, microvascular, and coronary artery disease.

Conclusions:

  • LVH significantly increases cardiovascular disease risk.
  • Understanding the pathophysiology of LVH is essential for clinical management.
  • Targeting mechanisms of ischemia in LVH patients is critical for improving outcomes.

Related Experiment Videos